公开(公告)号：US20190314335A1

公开(公告)日：2019-10-17

申请号：US16448069

申请日：2019-06-21

Applicant: FUJIFILM Corporation

Inventor： Yuta YOSHINO ,  Hayato OGURA ,  Mikinaga MORI ,  Taisuke ENDO ,  Kentaro NUMAJIRI ,  Ritsuko HORI

IPC: A61K31/4045 ,  A61K9/127 ,  A61K35/00

Abstract: An object of the present invention is to provide a lipid particle composition containing panobinostat or a salt thereof and exhibiting a high bone marrow-targeting capability, and a pharmaceutical composition including the lipid particle composition. According to the present invention, provided is a lipid particle composition containing panobinostat or a salt thereof, in which a lipid particle contains a phospholipid and cholesterol.

公开(公告)号：US20210386768A1

公开(公告)日：2021-12-16

申请号：US17459412

申请日：2021-08-27

Applicant: FUJIFILM Corporation

Inventor： Hidetoshi MURAO ,  Hayato OGURA ,  Koichi SAITO ,  Shinji HAGIWARA ,  Takeshi YAMAURA ,  Toshiyuki NAKATANI ,  Hitoshi KIYOI ,  Yuichi ISHIKAWA

IPC: A61K31/706 ,  A61K31/505 ,  A61K31/635

Abstract: An object of the present invention is to provide a combination medicine that exhibits a practical curing effect on a tumor such as acute myeloid leukemia. According to the present invention, there is provided a combination medicine, which contains a compound represented by General Formula [1] specified in the present specification, such as (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)-4-pentyn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methyl-2-butenamide or a salt thereof, and at least one selected from the group consisting of a BCL-2 inhibitor and a pyrimidine antimetabolite.